These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Antibacterial treatment of urinary tract infections with co-tetroxazin (sterinor)].
    Author: Reuter MA, Loenicker EM, Reuter HJ.
    Journal: Fortschr Med; 1981 May 07; 99(17):654-8. PubMed ID: 7016696.
    Abstract:
    In 100 patients with urinary tract infections the new benzyl-pyrimidine/sulphonamide combination Co-tetroxazin (Sterinor) was tested concerning its in vitro and in vivo action. In spite of the heterogenous cases (pyelonephritis 16%, obstructions 15%, prostatitis respectively urethritis 12% and cystitis 53%) and the relatively high average age (about 40% above the age of 60) a high therapeutic success was achieved. The clinical symptomatology improved up to 96% (respectively 83% without anymore pathological findings). This in vivo action correlated very well with the in vitro action in the agar diffusion test: fully sensitive 79%, moderately sensitive 15% and resistant only 6%. It is worth mentioning that the in vivo results with Sterinor were obtained with only 1/3 of the usual substance load (dosis) of the other benzylpyrimidine/sulphonamide combinations. This is due to the more favourable pharmacokinetic properties. Particularly in chronic patients, multi-morbidity and in elder patients this is clinically relevant. With this proven comparable clinical effect Co-tetroxazin is to be specified therefore to be more effective pharmacologically.
    [Abstract] [Full Text] [Related] [New Search]